Skip to main content
. 2014 Aug 30;9(1):270–281. doi: 10.1016/j.molonc.2014.08.008

Figure 2.

Figure 2

DA and D2R agonist treatment decreases tumor progression in an LLC1 murine lung cancer model. A–E: C57BL/6 wildtype (B–D) and D2R knockout (B–C) mice were orthotopically injected with 1 × 105 luciferase‐labeled murine LLC1 cells suspended in 80 μl PBS and Matrigel. After establishment of the lung tumor, mice were xenogen imaged four days post‐injection of LLC1 cells. Mice received daily intraperitoneal injections of PBS vehicle (control groups) or 50 mg/kg dopamine (B), 10 mg/kg quinpirole (C), or 5 mg/kg cabergoline (D) (treatment groups) for seven days. Mice were xenogen imaged following treatment. A: Experimental timeline. B–D: Quantitation of LLC1 tumor growth by determining the difference in relative luciferase units (RLU) before and after treatment. E: Pre‐ and post‐treatment xenogen images of vehicle‐ and cabergoline treated mice.